The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-Analysis

Journal of the American Academy of Dermatology

Volumn 69, Issue 3, 2013, Pages

  Minkis, Kira ^a   Garden, Benjamin C ^a   Wu, Shenhong ^b   Pulitzer, Melissa P ^a   Lacouture, Mario E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

adverse event; cancer; drug reaction; ipilimumab; melanoma; rash

Indexed keywords

IPILIMUMAB;

CANCER PATIENT; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INDICATION; EARLY INTERVENTION; HUMAN; INCIDENCE; MEDICAL SOCIETY; MELANOMA; META ANALYSIS; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; VITILIGO;

EID: 84882879837     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.12.963     Document Type: Article

References (21)

1. M.A. Morse Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb Curr Opin Mol Ther 7 2005 588 597
2. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
3. C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, and C. Garbe Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
4. A.A. Sarnaik, B. Yu, D. Yu, D. Morelli, M. Hall, and D. Bogle Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma Clin Cancer Res 17 2011 896 906
5. B.C. Carthon, J.D. Wolchok, J. Yuan, A. Kamat, D.S. Ng Tang, and J. Sun Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial Clin Cancer Res 16 2010 2861 2871
6. E.M. Hersh, S.J. O'Day, J. Powderly, K.D. Khan, A.C. Pavlick, and L.D. Cranmer A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma Invest New Drugs 29 2011 489 498
7. R.E. Royal, C. Levy, K. Turner, A. Mathur, M. Hughes, and U.S. Kammula Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma J Immunother 33 2010 828 833
8. J.D. Wolchok, B. Neyns, G. Linette, S. Negrier, J. Lutzky, and L. Thomas Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomized, double-blind, multicenter, phase 2, dose-ranging study Lancet Oncol 11 2010 155 164
9. J.C. Yang, M. Hughes, U. Kammula, R. Royal, R.M. Sherry, and S.L. Topalian Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis J Immunother 30 2007 825 830
10. D.P. Lawrence, O. Hamid, D.F. McDermott, I. Puzanov, M. Sznol, and J. Clark Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases [abstract] J Clin Oncol 28 Suppl 2010 15S
11. T.J. Lynch, I.N. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, and R.T. Chacko Phase II trial of ipilimumab and paclitaxel/carboplatin n first-line stage IIIb/IV non-small cell lung cancer [abstract] J Clin Oncol 28 Suppl 2010 15S
12. P. Attia, G.Q. Phan, A.V. Maker, M.R. Robinson, M.M. Quezado, and J.C. Yang Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 J Clin Oncol 23 2005 6043 6053
13. S.G. Downey, J.A. Klapper, F.O. Smith, J.C. Yang, R.M. Sherry, and R.E. Royal Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-Associated antigen-4 blockade Clin Cancer Res 13 2007 6681 6688
14. G.Y. Ku, J. Yuan, D.B. Page, S.E. Schroeder, K.S. Panageas, and R.D. Carvajal Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival Cancer 116 2010 1767 1775
15. J.S. Weber, S. O'Day, W. Urba, J. Powderly, G. Nichol, and M. Yellin Phase I/II study of ipilimumab for patients with metastatic melanoma J Clin Oncol 26 2008 5950 5956
16. I. Melero, S. Hervas-Stubbs, M. Glennie, D.M. Pardoll, and L. Chen Immunostimulatory monoclonal antibodies for cancer therapy Nat Rev Cancer 7 2007 95 106
17. H. Bour-Jordan, J.H. Esensten, M. Martinez-Llordella, C. Penaranda, M. Stumpf, and J.A. Bluestone Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family Immunol Rev 241 2011 180 205
18. S.H. Jaber, E.W. Cowen, L.R. Haworth, S.L. Booher, D.M. Berman, and S.A. Rosenberg Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent Arch Dermatol 142 2006 166 172
19. R. Gutzmer Cutaneous side effects of new antitumor drugs: clinical features and management Dtsch Arztebl Int 109 2012 133 140
20. K.C. Kähler, and A. Hauschild Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma J Dtsch Dermatol Ges 9 2011 277 286
21. J.S. Weber, K.C. Kähler, and A. Hauschild Management of immune-related adverse events and kinetics of response with ipilimumab J Clin Oncol 30 2012 2691 2697